Completed PHASE4 INTERVENTIONAL 2-arm NCT02305355

Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia

Sponsor: Kuhnil Pharmaceutical Co., Ltd.

Conditions Diabetes Mellitus, Type 2 Hypertriglycemia

Interventions Omega-3-acids ethylesters 90 4g Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin

Updated 6 times since 2017 Last updated: Dec 1, 2014 Started: Feb 28, 2009 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02305355, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and Hypertriglycemia and remains completed. Sponsored by Kuhnil Pharmaceutical Co., Ltd., it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kuhnil Pharmaceutical Co., Ltd.

Data source: Kuhnil Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bucheon-si, South Korea